natgillin/translations-raw huggingface dataset:
The adverse reactions considered at least possibly related to treatment from clinical study and postmarketing experience are listed below by body system organ class and frequency. 
Neželeni učinki, za katere se na podlagi kliničnih študij in izkušenj med trženjem meni, da obstaja vsaj možna povezanost z zdravljenjem, so navedeni spodaj glede na organske sisteme in pogostnost.
The vial is then gently swirled until contents have completely dissolved. 
Vialo nežno obračajte, dokler se vsebina popolnoma ne raztopi.
In a Phase 2 open-label study (GS-US-205-0162), 105 paediatric patients aged 3 months to < 18 years (24 patients aged 3 months to < 2 years; 25 patients aged 2 to < 6 years; 56 patients aged 6 to < 18 years) with CF and documented initial/new onset P. aeruginosa infection/colonisation received Cayston 3 times a day for a single course of 28 days. 
V odprti študiji faze 2 (GS-US-205-0162) je 105 pediatričnih bolnikov, starih od 3 mesece do < 18 let (24 bolnikov, starih od 3 mesece do < 2 leti; 25 bolnikov, starih od 2 do < 6 let; 56 bolnikov, starih 6 do < 18 let) s CF in dokumentirano novo/ponovljeno okužbo/kolonizacijo z bakterijo P. aeruginosa v enem 28-dnevnem ciklu prejemalo zdravilo Cayston 3-krat na dnevno.
What Cayston looks like and contents of the pack 
Izgled zdravila Cayston in vsebina pakiranja
or inhaled antipseudomonal antibiotics (84 versus 121, p = 0.004) than TNStreated patients. 
ali inhalacijskih antibiotikov proti bakterijam Pseudomonas (84 v primerjavi s 121, p = 0,004), kot v skupini, zdravljeni z RTN.
The Phase 2 and 3 placebo-controlled, registrational studies permitted comparison of plasma concentrations 1 hour post dose of Cayston by age (6 to 12 years, 13 to 17 years, and ≥ 18 years). 
Registracijske, s placebom kontrolirane študije faze 2 in faze 3 so omogočile primerjavo koncentracij v plazmi 1 uro po odmerku zdravila Cayston glede na starost (6 do 12 let, 13 do 17 let in ≥ 18 let).
In the limited subgroup of patients who received inhaled tobramycin for less than 84 days in the previous 12 months (n = 40), lung function improvements at Day 28 and across three 28-day treatment courses were numerically smaller among aztreonam-treated patients than TNS-treated patients. 
V omejeni podskupini bolnikov, ki so prejemali inhalirani tobramicin manj kot 84 dni v predhodnih 12 mesecih (n = 40), so bila izboljšanja pljučne funkcije 28. dan in v treh 28-dnevnih ciklih zdravljenja številčno manjša v skupini bolnikov, zdravljenih z aztreonamom, kot v skupini bolnikov, zdravljenih z RTN.
CP-AI-005 enrolled 246 adult (predominantly) and paediatric patients. 
CP-AI-005 V študiji CP-AI-005 je sodelovalo 246 odraslih (v večini) in pediatričnih bolnikov.
Solvent: 1 ml low density polyethylene ampoule. 
Vehikel: 1 ml ampula iz polietilena nizke gostote.
Aztreonam is known to be excreted renally and therefore administration of Cayston in patients with renal impairment (serum creatinine > 2 times upper limit of normal) should be undertaken with caution. 
Znano je, da se aztreonam izloča preko ledvic, zato je treba pri bolnikih z okvarjenim delovanjem ledvic (kreatinin v serumu > 2-kratna zgornja meja normale) zdravilo Cayston uporabljati previdno.
Do not use this medicine if you notice that the package has been tampered with. 
Ne uporabljajte tega zdravila, če opazite znake odpiranja embalaže.
However, decreased P. aeruginosa susceptibility was not predictive of clinical efficacy of Cayston during the study. 
Vendar pa na podlagi zmanjšane občutljivosti na povzročitelja P. aeruginosa ni bilo mogoče napovedati klinične učinkovitosti zdravljenja z zdravilom Cayston v obdobju študije.
A total of 79 patients who completed a 28-day treatment course and who did not receive an additional antipseudomonal antibiotic during the treatment period were evaluable 6 months after the end of treatment; of these, 58.2% (n = 46) remained free of P. aeruginosa throughout this time period. 
Skupaj 79 bolnikov, ki so končali 28-dnevni cikel zdravljenja, in ki niso prejemali dodatnih antipsevdomonskih antibiotikov v obdobju zdravljenja, je bilo 6 mesecev po koncu zdravljenja mogoče oceniti; med njimi jih bakterije P. aeruginosa ves čas tega obdobja ni imelo 58,2 % (n = 46).
The occurrence of rash may be indicative of an allergic reaction to aztreonam. 
Pojav izpuščaja je lahko znak alergijske reakcije na aztreonam.
Aztreonam binds to penicillin-binding proteins of susceptible bacteria, which leads to inhibition of bacterial cell wall synthesis, followed by filamentation and cell lysis. 
Aztreonam se veže na beljakovine občutljivih bakterij, ki vežejo penicilin, kar povzroča zaviranje sinteze bakterijskih celičnih sten, ki ji sledita filamentacija in razpad celic.
Solvent for Cayston Sodium Chloride 0.17% 
vehikel za zdravilo Cayston natrijev klorid 0,17 %
A 104-week rat inhalation toxicology study to assess the carcinogenic potential of ascending doses of aztreonamdemonstrated no drug-related increase in malignant tumours. 
V 104-tedenski študiji inhalacijske toksičnosti pri podganah za ocenitev kancerogenega potenciala naraščajočih odmerkov aztreonama niso opazili z zdravilom povezanega povečanja malignih tumorjev.
antipseudomonal antibiotics related to respiratory events compared to TNS-treated patients (p = 0.0025). 
antibiotikov proti bakterijam Pseudomonas, povezanih z respiratornimi dogodki, v primerjavi z bolniki, zdravljenimi z RTN (p = 0,0025).
Press down and turn the cap clockwise as far as it will go (Figure 3b). 
Pokrov za zdravilo pritisnite navzdol in ga obračajte v smeri urnega kazalca, dokler gre (slika 3b).
Paediatric patients had clinical improvements with aztreonamas determined by an increase in FEV1, improvement in CFQ-R respiratory symptoms scores and decline in P. aeruginosa sputum density. 
Pri pediatričnih bolnikih so bila klinična izboljšanja z aztreonamom ugotovljena s povečanjem FEV1, izboljšanjem rezultatov respiratornih simptomov CFQ-R in zmanjšanjem gostote P. aeruginosa v izpljunku.
It's best to use Cayston immediately after you have made up the solution. 
Najboljše je, da zdravilo Cayston uporabite takoj, ko ste pripravili raztopino.
Treatment-emergent persistent isolation (defined as absent at screening/baseline then present at 3 or more subsequent consecutive visits) of MSSA occurred in 6% of aztreonam-treated patients compared to 3% of TNS-treated patients. 
Persistentna izolacija MSSA, ki se je pojavila ob zdravljenju (opredeljena kot odsotnost pri presejanju/izhodišču, nato pa prisotna pri 3 ali več naslednjih zaporednih obiskih), se je pojavila pri 6 % bolnikov, zdravljenih z aztreonamom, v primerjavi s 3 % bolnikov, zdravljenih z RTN.
Cayston contains the active substance aztreonam. 
Zdravilo Cayston vsebuje učinkovino aztreonam.
Do not stop taking Cayston without first talking to your doctor. 
Ne prenehajte jemati zdravila Cayston brez posveta z zdravnikom.
The known mechanism of resistance to aztreonam mediated by acquisition of genes involves acquisition of extended spectrum beta-lactam enzymes (ESBLs) that hydrolyse the fourmember, nitrogen-containing ring of aztreonam. 
Znan mehanizem odpornosti na aztreonam, ki ga povzroči pridobivanje genov, zajema pridobivanje betalaktam encimov z razširjenim spektrom (ESBL - extended spectrum beta-lactam enzymes), ki hidrolizira štiričlanski obroč aztreonama, ki vsebuje dušik.
Do not completely tear through the metal seal. 
Kovinskega tesnila ne smete v celoti pretrgati.
The use of Cayston in paediatric CF patients has been associated with haemoptysis during treatment cycles and could have aggravated underlying conditions. 
Uporaba zdravila Cayston pri pediatričnih bolnikih s CF je bila v ciklih zdravljenja povezana s hemoptizo in je lahko poslabšala osnovne bolezni.
Safely dispose of the metal seal. 
Varno odstranite kovinsko tesnilo.
Sodium chloride Water for injections 
Vehikel natrijev klorid voda za injekcije
Gently tap the amber vial containing the Cayston so that the powder settles at the bottom. 
Nežno potolcite po rjavi viali, ki vsebuje zdravilo Cayston, da se prašek usede na dnu.
Replacing the Altera Nebuliser Handset 
Zamenjava pršilnika nebulatorja Altera
Next, gently swirl the vial until the powder has completely dissolved and the liquid is clear. 
Nato nežno obračajte vialo, dokler se prašek povsem ne raztopi in ne dobite bistre tekočine.
Development of resistance during inhaled aztreonam therapy could limit treatment options during acute exacerbations. 
Razvoj odpornosti med inhalacijsko terapijo z aztreonamom lahko omeji možnosti zdravljenja med akutnimi poslabšanji.
The in vitro antimicrobial susceptibility test methods used for parenteral aztreonam therapy can be used to monitor the susceptibility of P. aeruginosa isolated from CF patients. 
Metode preskušanja antimikrobne občutljivosti in vitro, uporabljene za parenteralno terapijo z aztreonamom, se lahko uporabljajo za nadziranje občutljivosti povzročitelja P. aeruginosa, izoliranega iz bolnikov s CF.
Tabulated summary of adverse reactions 
Tabelarični povzetek neželenih učinkov
Aztreonam is not extensively metabolised. 
Aztreonam se ne presnavlja obsežno.
Non-clinical data for aztreonam for injection about fertility do not indicate any adverse effects. 
Predklinični podatki o vplivu aztreonama za injiciranje na plodnost ne kažejo na neželene učinke.
Rash has been reported with the use of Cayston and may be indicative of an allergic reaction to aztreonam (see section 4.4). 
Poročali so o izpuščaju, ki se je pojavil po uporabi zdravila Cayston, kar je lahko znak alergijske reakcije na aztreonam (glejte poglavje 4.4).
The liquid is squeezed out of one solvent ampoule into the glass vial. 
Tekočino iz ene ampule z vehiklom iztisnite v stekleno vialo.
- The solvent ampoule contains water for injections and sodium chloride. 
- Ampula z vehiklom vsebuje vodo za injekcije in natrijev klorid.
Preparing your Cayston for inhalation 
Priprava zdravila Cayston za inhaliranje
In the two Phase 3 placebo-controlled clinical studies where patients received Cayston for 28 days, the most frequently occurring adverse reactions to Cayston were cough (58%), nasal congestion (18%), wheezing (15%), pharyngolaryngeal pain (13.0%), pyrexia (12%) and dyspnoea (10%). 
V dveh s placebom kontroliranih kliničnih študijah faze 3, v katerih so bolniki zdravilo Cayston prejemali 28 dni, so bili najpogostejši neželeni učinki povezani z zdravilom Cayston kašelj (58%), zamašen nos (18%), sopenje (15%), faringolaringalna bolečina (13%), pireksija (12%) in dispneja
Bronchospasm 
Bronhospazem
During the 6-month randomised phase of study GS-US-205-0110, treatment-emergent isolation of MSSA and MRSA was observed more commonly among aztreonam-treated patients than Tobramycin Nebuliser Solution (TNS)-treated patients. 
Med 6-mesečno randomizirano fazo študije GS-US-205-0110, so izolacijo MSSA in MRSA, ki se je pojavila ob zdravljenju, pri bolnikih, zdravljenih z aztreonamom, opazili bolj pogosto kot pri bolnikih, zdravljenih z raztopino tobramicina za nebulator (RTN).
Since the plasma concentration of aztreonam following administration of Cayston (75 mg) is approximately 0.6 µg/ml, compared to serum levels of 54 µg/ml following administration of aztreonam for injection (500 mg), no safety issues associated with aztreonam overdose are anticipated. 
Ker je koncentracija aztreonama v plazmi po uporabi zdravila Cayston (75 mg) približno 0,6 µg/ml v primerjavi z ravnjo v serumu 54 µg/ml po uporabi aztreonama za injiciranje (500 mg), ni za pričakovati težav z varnostjo, povezanih s prevelikim odmerjanjem aztreonama.
If you stop taking Cayston 
Če ste prenehali uporabljati zdravilo Cayston
cough, nasal congestion, wheezing, pharyngolaryngeal pain, dyspnoea 
kašelj, zamašen nos, sopenje, faringolaringalna bolečina, dispneja
An association between persistent isolation of MRSA and more severe disease and increased mortality has been reported in the literature. 
V literaturi poročajo o povezavi med persistentno izolacijo MRSA in hujšo boleznijo in povečano smrtnostjo.
Treatment-emergent intermittent isolation of MRSA occurred in 7% of aztreonam-treated patients compared to 1% of TNS-treated patients and treatment-emergent persistent isolation of MRSA occurred in 3% of aztreonam-treated patients compared to no TNS-treated patients. 
Prehodna izolacija MRSA, ki se je pojavila ob zdravljenju, se je pojavila pri 7 % bolnikov, zdravljenih z aztreonamom, v primerjavi z 1 % bolnikov, zdravljenih z RTN in persistentna izolacija MRSA, ki se je pojavila ob zdravljenju, se je pojavila pri 3 % bolnikov, zdravljenih z aztreonamom, v primerjavi z nič bolniki, zdravljenimi z RTN.
Pooled sputum concentration data from the Phase 2 and 3 registrational studies revealed some evidence of lower mean sputum concentrations in patients aged 13 to 17 years following one dose of Cayston 3 times a day. 
Združeni podatki koncentracij v izpljunku iz registracijskih študij faze 2 in faze 3 so razkrili nekatere dokaze o nižjih srednjih koncentracijah v izpljunku pri bolnikih, starih 13 do 17 let, po enem odmerku zdravila Cayston 3-krat dnevno.
Cayston is indicated for use in paediatric patients aged 6 years and older with repeated cycles of 28 days on therapy followed by 28 days off Cayston therapy based on the above clinical experience. 
Zdravilo Cayston je indicirano za uporabo pri pediatričnih bolnikih, starih 6 let in več, v ponavljajočih 28-dnevnih ciklih zdravljenja, ki jim sledi 28-dnevno obdobje brez jemanja zdravila Cayston, na podlagi zgoraj navedenih kliničnih izkušenj.
Studies were conducted using the Altera Nebuliser System to administer Cayston. 
Študije so izvajali s sistemom nebulatorja Altera za dajanje zdravila Cayston.
Over nine 28-day courses of therapy, measures of pulmonary function (FEV1), CFQ-R respiratory symptoms scores, and P. aeruginosa sputum density showed a trend to improvement while the patients were on treatment compared with off treatment. 
V devetih 28-dnevnih ciklih zdravljenja so meritve pljučne funkcije (FEV1), rezultatov respiratornih simptomov CFQ-R in gostote P. aeruginosa v izpljunku v času zdravljenja pokazali trend izboljšanja v primerjavi z rezultati v času, ko bolniki niso prejemali zdravila.
Patients should use a bronchodilator before each dose of Cayston. 
Bolniki morajo pred vsakim odmerkom zdravila Cayston uporabiti bronhodilatator.
If you forget to take Cayston 
Če ste pozabili uporabiti zdravilo Cayston
- Do not prepare Cayston until you are ready to administer a dose. 
- Zdravila Cayston ne pripravite, če niste pripravljeni na uporabo odmerka.
The elimination half-life of aztreonam from serum is approximately 2.1 hours for inhalation administration, similar to what has been reported for aztreonam for injection. 
Razpolovni čas izločanja aztreonama iz seruma je približno 2,1 ure za uporabo z inhaliranjem, kar je podobno kot izločanje aztreonama, uporabljenega z injiciranjem.
A total of 137 paediatric patients aged 6 to 17 years with chronic P. aeruginosa infection and FEV1 ≤ 75% predicted have received Cayston in Phase 2 and Phase 3 clinical studies. 
Skupaj 137 pediatričnih bolnikov, starih 6 do 17 let, s kronično okužbo z bakterijo P. aeruginosa in z napovedanim odstotkom FEV1 ≤ 75 %, je prejelo zdravilo Cayston v kliničnih študijah faze 2 in faze 3.
May be stored outside a refrigerator but below 25°C for up to 28 days. 
Lahko shranjujete zunaj hladilnika na temperaturi do 25 °C do 28 dni.
Using one hand to hold the vial steady, use the other hand to slowly flip up the blue cap. 
Z eno roko trdno držite vialo, z drugo roko pa počasi privzdignite modro zaporko.
Aztreonam-treated patients also demonstrated larger mean improvements in CFQ-R respiratory symptoms scores compared to TNS-treated patients across 3 treatment courses (6.30 versus 2.17, p = 0.019). 
Pri bolnikih, zdravljenih z aztreonamom, je bilo srednje izboljšanje rezultatov respiratornih simptomov CFQ-R v primerjavi z bolniki, zdravljenimi z RTN, v vseh 3 ciklih zdravljenja boljše (6,30 v primerjavi z 2,17, p = 0,019).
All patients were treated with Tobramycin Nebuliser Solution (TNS) 300 mg, 2 times a day in the four weeks immediately prior to receiving Cayston or placebo either 2 or 3 times a day for 28 days. 
Vse bolnike so zdravili z raztopino tobramicina za nebulator (RTN) v odmerku 300 mg, 2-krat na dan, štiri tedne preden so prejemali zdravilo Cayston ali placebo 2-krat ali 3-krat na dan, 28 dni.
The development of antibiotic-resistant P. aeruginosa and superinfection with other pathogens represent potential risks associated with antibiotic therapy. 
Razvoj proti antibiotikom odpornega povzročitelja P. aeruginosa in superinfekcij z drugimi patogeni predstavlja potencialna tveganja, povezana z zdravljenjem z antibiotiki.
Talk to your doctor before taking Cayston: - if you are allergic to any other antibiotics (such as penicillins, cephalosporins, and/or carbapenems) - if you do not tolerate or have chest tightness from taking other inhaled medicines 
Pred začetkom uporabe zdravila Cayston se posvetujte z zdravnikom: - če ste alergični na druge antibiotike (kot so penicilini, cefalosporini in/ali karbapenemi) - če ne prenašate drugih zdravil za inhaliranje, ali če zaradi njih čutite stiskanje v prsnem košu - če imate težave z ledvicami - če ste kadar koli izkašljali kri - če ste kadar koli imeli nizke rezultate testa pljučne funkcije.
If not used immediately, the reconstituted solution must be stored at 2°C - 8°C and used within 8 hours. 
Rekonstituirano raztopino, ki je ne porabite takoj, morate shranjevati v hladilniku na 2 °C − 8 °C in uporabiti v 8 urah.
Administration of Cayston in CF patients with active haemoptysis should be undertaken only if the benefits of treatment are considered to outweigh the risks of inducing further haemorrhage. 
Zdravilo Cayston se sme bolnikom s CF z aktivno hemoptizo dajati le, če so koristi zdravljenja večje od tveganj za povzročitev nadaljnje krvavitve.
Pour all of the prepared Cayston from the vial into the Altera Nebuliser Handset medicine reservoir (Figure 3a). 
Celotno količino pripravljenega zdravila Cayston vlijte iz viale v vsebnik za zdravilo kompleta z nebulatorjem Altera (slika 3a).
An increased prevalence of methicillin-resistant Staphylococcus aureus (MRSA), methicillin-sensitive S. aureus (MSSA), Aspergillus and Candida species was observed over time in patients treated with several Cayston treatment courses. 
Čez čas so opazili povečano razširjenost vrst proti meticilinu odpornih Staphylococcus aureus (methicillin-resistant Staphylococcus aureus, MRSA), na meticilin občutljivih S. aureus (methicillinsensitive S. Aureus, MSSA), Aspergillus in Candida pri bolnikih, zdravljenih z zdravilom Cayston v več ciklih zdravljenja.
In the Phase 3 placebo-controlled studies of Cayston, local aztreonam concentrations generally exceeded aztreonam MIC values for P. aeruginosa, regardless of the level of P. aeruginosa susceptibility. 
V s placebom kontroliranih študijah faze 3 zdravila Cayston so lokalne koncentracije aztreonama običajno presegle vrednosti MIK aztreonama za povzročitelja P. aeruginosa, neodvisno od stopnje občutljivosti povzročitelja P. aeruginosa.
If not used immediately, the prepared solution must be stored at 2°C - 8°C and used within 8 hours. 
Pripravljeno raztopino, ki je ne porabite takoj, morate shranjevati v hladilniku na 2 °C - 8 °C in uporabiti v 8 urah.
What you need to know before you take Cayston Do not take Cayston 
Kaj morate vedeti, preden boste uporabili zdravilo Cayston Ne uporabljajte zdravila Cayston:
One plastic ampoule of solvent (0.17% w/v sodium chloride). 
eno plastično ampulo vehikla (0,17% m/v natrijevega klorida).
Of the 101 patients, all having a positive cultures for P. aeruginosa within 30 days of study enrolment, of whom 56 (55.4%) were free of P. aeruginosa at baseline who completed a 28-day treatment course 89.1% (n = 90) were free of P. aeruginosa at the end of treatment (Day 28) and 75.2% (n = 76) were free of P. aeruginosa 1 month after the end of treatment (Day 56). 
Med 101 bolnikom, ki so imeli vsi pozitivne kulture za bakterijo P. aeruginosa v 30 dneh po vključitvi v študijo, in med katerimi jih 56 (55,4 %) ob izhodišču ni imelo bakterije P. aeruginosa, ki so dokončali 28-dnevni cikel zdravljenja, jih ob koncu zdravljenja 89,1 % (n = 90) ni imelo bakterije P. aeruginosa (28. dan) in 75,2 % (n = 76) jih 1 mesec po koncu zdravljenja (56. dan) ni imelo bakterije P. aeruginosa.
Do not twist the blue cap. 
Modre zaporke ne smete zvijati.
bronchospasm1, chest discomfort, rhinorrhoea, haemoptysis1 Skin and subcutaneous tissue disorders: Common: 
bronhospazem1, bolečine v prsih, rinoreja, hemoptiza1 Bolezni kože in podkožja:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CAYSTON INNER CARTON 
PODATKI NA ZUNANJI OVOJNINI CAYSTON NOTRANJA ŠKATLA
Peak levels of aztreonam are achieved at about one hour after i.m. 
Farmakokinetične lastnosti aztreonama za injiciranje Najvišje ravni aztreonama so dosežene približno eno uro po i.m.
It is recommended that Cayston be administered immediately after reconstitution with solvent. 
Priporoča se, da se zdravilo Cayston uporabi takoj po rekonstituciji z vehiklom.
Do not reconstitute or mix Cayston with any other solvent or medicinal product. 
Zdravila Cayston ne rekonstituirajte in ne mešajte z drugimi vehikli ali zdravili.
In a 24-week active-controlled clinical study of Cayston therapy, increases were observed in the MIC90 for all P. aeruginosa isolates as well as in the percentages of patients with P. aeruginosa resistant (MIC above the parenteral breakpoint) to aztreonam, to at least 1 beta-lactam antibiotic, and to all 6 beta-lactam antibiotics tested (see section 5.1). 
V 24-tedenski aktivno kontrolirani klinični študiji zdravljenja z zdravilom Cayston so opazili povečanje MIK90 za vse izolate povzročitelja P. aeruginosa in povečanje odstotka bolnikov s povzročiteljem P. aeruginosa, odpornim (MIK nad parenteralno mejno vrednostjo) na aztreonam, na vsaj 1 betalaktamski antibiotik in na vseh 6 testiranih betalaktamskih antibiotikov (glejte poglavje 5.1).
Cayston should not be reconstituted until a dose is ready to be administered. 
Zdravilo Cayston se ne sme rekontituirati, dokler bolnik ni pripravljen na uporabo odmerka.
One glass vial containing Cayston is opened by carefully removing the blue cap and the metal ring, and then the grey rubber stopper. 
Eno stekleno vialo, ki vsebuje zdravilo Cayston, odprite tako, da previdno odstranite modro zaporko in kovinski obroček ter nato še siv gumijast zamašek.
The unopened vials may also be stored outside the refrigerator but below 25°C for up to 28 days. 
Neodprte viale lahko shranjujete tudi zunaj hladilnika na temperaturi do 25 °C do 28 dni.
After reconstitution, immediate use of Cayston is recommended. 
Priporoča se, da rekonstituirano raztopino zdravila Cayston takoj uporabite.
EU/1/09/543/001: 28-day pack of Cayston 
EU/1/09/543/001: 28-dnevni paket zdravila Cayston
After a few seconds, an aerosol mist will begin to flow into the Aerosol Chamber of the Altera Nebuliser Handset. 
Po nekaj sekundah bo začel v komoro za aerosol kompleta z nebulatorjem Altera pršeti aerosol.
Lung function test decreased 
Poslabšanje testa pljučne funkcije
Patients were randomised in a 2:2:1:1 ratio to be treated with aztreonam 75 mg 2 or 3 times a day or volume-matched placebo 2 or 3 times a day for 28 days immediately following the 28-day lead-in course of open-label TNS. 
Bolnike so naključno razporedili v razmerju 2:2:1:1, tako da so prejemali aztreonam 75 mg 2-krat ali 3-krat na dan, ali ustrezno prostornino placeba 2-krat ali 3-krat na dan, 28 dni takoj po 28-dnevnem uvodnem ciklu zdravljenja odprtega prejemanja RTN.
Individual patients' plasma aztreonam concentrations exhibited considerable variability. 
Koncentracije aztreonama v plazmi posameznih bolnikov so kazale velika nihanja.
If any of these apply to you tell your doctor before using Cayston. 
Če kar koli od naštetega velja za vas, obvestite svojega zdravnika, preden uporabite zdravilo
Sputum concentrations 
Koncentracije izpljunka